Objective: The clinical profile of late-life depression (LLD) is frequently associated with cognitive impairment, aging-related brain changes, and somatic comorbidity. This two-site naturalistic longitudinal study aimed to explore differences in clinical and brain characteristics and response to electroconvulsive therapy (ECT) in early- (EOD) versus late-onset (LOD) late-life depression (respectively onset <55 and ≥55 years).
Methods: Between January 2011 and December 2013, 110 patients aged 55 years and older with ECT-treated unipolar depression were included in The Mood Disorders in Elderly treated with ECT study. Clinical profile and somatic health were assessed. Magnetic resonance imaging (MRI) scans were performed before the first ECT and visually rated.
Results: Response rate was 78.2% and similar between the two sites but significantly higher in LOD compared with EOD (86.9 versus 67.3%). Clinical, somatic, and brain characteristics were not different between EOD and LOD. Response to ECT was associated with late age at onset and presence of psychotic symptoms and not with structural MRI characteristics. In EOD only, the odds for a higher response were associated with a shorter index episode.
Conclusion: The clinical profile, somatic comorbidities, and brain characteristics in LLD were similar in EOD and LOD. Nevertheless, patients with LOD showed a superior response to ECT compared with patients with EOD. Our results indicate that ECT is very effective in LLD, even in vascular burdened patients.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.jagp.2016.09.005 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Comparison of EEG Signal Spectral Characteristics Obtained with Consumer- and Research-Grade Devices.
Sensors (Basel)
December 2024
Abu Dhabi Maritime Academy, Abu Dhabi P.O. Box 54477, United Arab Emirates.
Electroencephalography (EEG) has emerged as a pivotal tool in both research and clinical practice due to its non-invasive nature, cost-effectiveness, and ability to provide real-time monitoring of brain activity. Wearable EEG technology opens new avenues for consumer applications, such as mental health monitoring, neurofeedback training, and brain-computer interfaces. However, there is still much to verify and re-examine regarding the functionality of these devices and the quality of the signal they capture, particularly as the field evolves rapidly.
View Article and Find Full Text PDFMolecular Targeting of Ischemic Stroke: The Promise of Naïve and Engineered Extracellular Vesicles.
Pharmaceutics
November 2024
Laboratory of Stem Cells and Tissue Regeneration, Department of Biotechnology, College of Life Sciences and Biotechnology, Korea University, Seoul 02841, Republic of Korea.
Ischemic stroke (IS) remains a leading cause of mortality and long-term disability worldwide, with limited therapeutic options available. Despite the success of early interventions, such as tissue-type plasminogen activator administration and mechanical thrombectomy, many patients continue to experience persistent neurological deficits. The pathophysiology of IS is multifaceted, encompassing excitotoxicity, oxidative and nitrosative stress, inflammation, and blood-brain barrier disruption, all of which contribute to neural cell death, further complicating the treatment of IS.
View Article and Find Full Text PDFThe Improvement in Sleep Quality by Zizyphi Semen in Rodent Models Through GABAergic Transmission Regulation.
Nutrients
December 2024
Department of Molecular Medicine, School of Medicine, Ewha Womans University, Seoul 07804, Republic of Korea.
: Sleep, a process physiologically vital for mental health, faces disruptions in various sleep disorders linked to metabolic and neurodegenerative risks. seed (Zizy) has long been recognized for its diverse pharmacological attributes, including analgesic, sedative, insomnia, and anxiety alleviation. : In this study, the sleep-prolonging effects of Zizy extract (100, 200 mg/kg), along with their characterizing compounds jujuboside A (JuA) (5, 10 mg/kg), were evaluated in a mouse model under a pentobarbital-induced sleep.
View Article and Find Full Text PDFA Repurposed Drug Selection Pipeline to Identify CNS-Penetrant Drug Candidates for Glioblastoma.
Pharmaceuticals (Basel)
December 2024
Department of Neurosurgery, Brain Tumor Center, Erasmus MC Cancer Institute, Erasmus University Medical Center, 3015 GD Rotterdam, The Netherlands.
Background: Glioblastoma is an aggressive and incurable type of brain cancer. Little progress has been made in the development of effective new therapies in the past decades. The blood-brain barrier (BBB) and drug efflux pumps, which together hamper drug delivery to these tumors, play a pivotal role in the gap between promising preclinical findings and failure in clinical trials.
View Article and Find Full Text PDFRecent Advancements in 2D Material-Based Memristor Technology Toward Neuromorphic Computing.
Micromachines (Basel)
November 2024
Department of Microdevice Engineering, Korea University, Seoul 02841, Republic of Korea.
Two-dimensional (2D) layered materials have recently gained significant attention and have been extensively studied for their potential applications in neuromorphic computing, where they are used to mimic the functions of the human brain. Their unique properties, including atomic-level thickness, exceptional mechanical stability, and tunable optical and electrical characteristics, make them highly versatile for a wide range of applications. In this review, we offer a comprehensive analysis of 2D material-based memristors.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!